1437774-69-0

Basic information

• Product Name: tert-butyl 4-(2-pyrrolidin-1-ylethoxymethyl)piperidine-1-carboxylate
• Synonyms: tert-butyl 4-(2-pyrrolidin-1-ylethoxymethyl)piperidine-1-carboxylate
• CAS NO: 1437774-69-0
• Molecular Weight: 312.453
• Mol File: 1437774-69-0.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(2-pyrrolidin-1-ylethoxymethyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(2-pyrrolidin-1-ylethoxymethyl)piperidine-1-carboxylate(1437774-69-0)
• EPA Substance Registry System: tert-butyl 4-(2-pyrrolidin-1-ylethoxymethyl)piperidine-1-carboxylate(1437774-69-0)

Safety Data

• Hazardous Substances Data: 1437774-69-0(Hazardous Substances Data)

Upstream product

• 5050-41-9 N-(2-chloroethyl)-pyrrolidine 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 7250-67-1 1-(2-chloroethyl)pyrrolidine hydrochloride 

Downstream Products

• 1436613-26-1 N-[(Z)-[(2,5-dibromo-4-phenyl-3-thienyl)-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]methylene]amino]-4-methyl-benzenesulfonamide 
• 1437771-81-7 N,N-dimethyl-5-phenyl-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-d]pyrimidine-6-carboxamide 
• 1437771-88-4 3-phenyl-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-b]pyridine 
• 1437771-94-2 5-phenyl-2-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-d]pyrimidine 
• 1437772-06-9 N-[5-phenyl-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-d]pyrimidin-6-yl]acetamide 
• 1437774-63-4 6-bromo-5-phenyl-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-d]pyrimidine 
• 1437771-86-2 N-isopropyl-5-phenyl-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-d]pyrimidine-6-carboxamide 
• 1437774-62-3 5-phenyl-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-d]pyrimidine-6-carboxylic acid 
• 1437774-61-2 methyl 5-phenyl-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-d]pyrimidine-6-carboxylate 
• 1437773-27-7 [5-phenyl-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-d]pyrimidin-6-yl]methanol 
• 1437773-47-1 5-phenyl-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]furo[2,3-d]pyrimidine 
• 1437774-88-3 2-methylsulfonyl-5-phenyl-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]furo[2,3-d]pyrimidine 
• 1437773-79-9 5-phenyl-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]-2-(trifluoromethyl)thieno[2,3-d]pyrimidine 
• 1437773-96-0 2-cyclopropyl-5-(2-methoxyphenyl)-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-d]pyrimidine 

Relevant articles and documents

THIENO (2,3 - C) PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS

The present invention provides compounds of formula (I): wherein A, R1, R2, R3 IX, and Z are defined herein, which are potassium channel inhibitors. The invention further provides pharmaceutical compositions comprising the compounds of formula (I) and their use in therapy, in particular in treatment of diseases or conditions that are mediated by Kir3.1 and/or Kir3.4 or any heteromultimers thereof, or that require inhibition of Kir3.1 and/or Kir3.4 or any heteromultimers thereof.

THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS

The present invention provides compounds of formula (I): (Formula (I); wherein A, R1, R2, R3I, V, X, and Z are defined herein, which are potassium channel inhibitors. The invention further provides pharmaceutical compositions comprising the compounds of formula (I) and their use in therapy, in particular in treatment of diseases or conditions that are mediated by Kir3.1 and/or Kir3.4 or any heteromultimers thereof, or that require inhibition of Kir3.1 and/or Kir3.4 or any heteromultimers thereof.

THIENO [2, 3 - C] PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS

The present invention provides compounds of formula (I): wherein A, R1, R2, R3IX, and Z are defined herein, which are potassium channel inhibitors. The invention further provides pharmaceutical compositions comprising the compounds of formula (I) and their use in therapy, in particular in treatment of diseases or conditions that are mediated by Kir3.1 and/or Kir3.4 or any heteromultimers thereof, or that require inhibition of Kir3.1 and/or Kir3.4 or any heteromultimers thereof.